Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Current Report · Items 5.02 · 8-K

Scorpius Holdings, Inc.

SCPXOTCEQUITYCurrent

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 21, 2026, John Monahan, Ph.…

Filed Apr 24, 2026Accepted Apr 24, 2026, 5:16 PM EDTCIK 1476963Accession 0001079973-26-000533
Share

Company context

We are a contract development and manufacturing organization (“CDMO”) that provides a comprehensive range of biologics manufacturing services from process development to Current Good Manufacturing Practices (“cGMP”) clinical and commercial manufacturing of biologics for the biotechnology and biopharmaceutical industries. Scorpius pairs cGMP biomanufacturing and quality control expertise with cutting edge capabilities in immunoassays, molecular assays, and bioanalytical methods to support the production of cell- and gene-based therapies as well as large molecule biologics. Our services include clinical and commercial drug substance manufacturing, release and stability testing and variety of process development services, including upstream and downstream development and optimization, analytical method development, cell line development, testing and characterization. Our San Antonio, TX facility commenced operations in October 2022.

Current securities

Historical securities (1)

Recent company filings

  1. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsApr 8, 2026
  2. Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity SecuritiesMar 19, 2026
  3. Completion of Acquisition or Disposition of Assets · Triggering Events That Accelerate or Increase a Direct Financial ObligationMar 10, 2026
  4. 10-Q filingFeb 17, 2026
  5. SCHEDULE 13G/A - filed by 3i, LP regarding Scorpius Holdings, Inc.Feb 5, 2026

Disclosure sections

Items 5.02

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 21, 2026, John Monahan, Ph. D., a member of the Board of Directors (the “Board”) of Scorpius Holdings, Inc., a Delaware corporation (the “Company”), notified the Company of his decision to resign, effective immediately, from his position as a member of the Board and related Committees. Mr. Monahan did not advise the Company of any disagreement with the Company on any matter relating to its operations, policies or practices. Mr. Monahan served as a non-employee director, Chairman of the Compensation Committee of the Board, and a member of the Audit Committee of the Board and the Nominating and Governance Committee of the Board. On April 23, 2026, Edward B. Smith, III, a member of the Board, notified the Company of his decision to resign, effective immediately, from his position as a member of the Board and related Committees. Mr. Smith did not advise the Company of any disagreement with the Company on any matter relating to its operations, policies or practices. Mr. Smith served as a non-employee director, Chairman of the Audit Committee and the Nominating and Governance Committee of the Board, and a member of the Compensation Committee of the Board. In addition, on April 23, 2026, Kit Foo Chye, a member of the Board, notified the Company of his decision to resign, effective immediately, from his position as a member of the Board. Mr. Chye did not advise the Company of any disagreement with the Company on any matter relating to its operations, policies or practices. Mr. Chye served as a non-employee director and was not a member of any committees of the Board.